Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center
|
April 14, 2025
Pre-Surgical Education and Discharge Planning for Head and Neck Cancer: A Qualitative Study of Patient and Caregiver Perspectives
Ameer Basta, Marian Mikhael, Bhargav Kansara, et al.
Applied Clinical Informatics
|
May 22, 2024
Suicide Risk Screening for Head and Neck Cancer Patients: An Implementation Study
Bhargav Kansara, Ameer Basta, Marian Mikhael, et al.
Head & Neck
|
March 9, 2024
Optimizing presurgical education for patients with head and neck cancer receiving laryngectomy and free flap surgery: A qualitative study
Marian Mikhael, Bhargav Kansara, Ameer Basta, et al.
Oncology
|
August 4, 2025
A real-world single-center cohort study on the tolerability of trastuzumab deruxtecan for HER2+ metastatic breast cancer
Ameer Basta, Kyle Lien, Weihong Sun, et al.
Nature Communications
|
May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Cancer Control : Journal of the Moffitt Cancer Center
|
April 14, 2025
Pre-Surgical Education and Discharge Planning for Head and Neck Cancer: A Qualitative Study of Patient and Caregiver Perspectives
Ameer Basta, Marian Mikhael, Bhargav Kansara, et al.
Applied Clinical Informatics
|
May 22, 2024
Suicide Risk Screening for Head and Neck Cancer Patients: An Implementation Study
Bhargav Kansara, Ameer Basta, Marian Mikhael, et al.
Head & Neck
|
March 9, 2024
Optimizing presurgical education for patients with head and neck cancer receiving laryngectomy and free flap surgery: A qualitative study
Marian Mikhael, Bhargav Kansara, Ameer Basta, et al.
Oncology
|
August 4, 2025
A real-world single-center cohort study on the tolerability of trastuzumab deruxtecan for HER2+ metastatic breast cancer
Ameer Basta, Kyle Lien, Weihong Sun, et al.
Nature Communications
|
May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, et al.
Page
of 1